Status:

TERMINATED

Safety and Tolerability of RTX-134 in Adults With Phenylketonuria

Lead Sponsor:

Rubius Therapeutics

Conditions:

Phenylketonurias

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This study will evaluate the safety and tolerability of RTX-134 in adult patients with PKU.

Detailed Description

This is a Phase 1b first-in-human trial in adult subjects with PKU. The primary objective of this study is to evaluate the safety and tolerability of RTX-134 following intravenous administration of a ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Age 18 years or older with:
  • A clinical diagnosis of PKU, and
  • Average blood phenylalanine level ≥ 600 µmol/L based on 2 assessments up to 3 weeks apart during the 6-month period before Day 0 (per available data)
  • Stable diet, including medical formula
  • Must be a man or a woman not of childbearing potential and agree to use adequate contraception throughout and for one year following study participation.
  • Adequate organ function
  • Negative antibody detection on type and screen and no evidence of clinical hemolysis
  • Exclusion Criteria
  • Known hypersensitivity to any component of study treatment
  • Prior treatment with Pegaliase
  • Start of sapropterin dihydrochloride within 3 weeks of study dosing
  • Use of an investigational agent within 28 days of study dosing
  • Concurrent participation in an interventional trial involving ongoing treatment, including placebo.
  • Infections requiring antimicrobial treatment within 7 days of study dosing
  • Chronic infections, such as HIV, hepatitis B, or untreated hepatitis C
  • Conditions that may alter survival of red blood cells, (e.g., autoimmune diseases, splenectomy, etc)
  • Pregnant or breastfeeding

Exclusion

    Key Trial Info

    Start Date :

    January 29 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2022

    Estimated Enrollment :

    1 Patients enrolled

    Trial Details

    Trial ID

    NCT04110496

    Start Date

    January 29 2020

    End Date

    December 1 2022

    Last Update

    December 8 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Children's Hospital Colorado

    Aurora, Colorado, United States, 80045